BLCO vs. SNN, SOLV, PEN, STVN, GKOS, NARI, IRTC, TMDX, INSP, and SLNO
Should you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Smith & Nephew (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Inspire Medical Systems (INSP), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.
Bausch + Lomb vs. Its Competitors
Bausch + Lomb (NYSE:BLCO) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking.
11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew shares are owned by institutional investors. 0.8% of Bausch + Lomb shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Smith & Nephew received 408 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 54.10% of users gave Smith & Nephew an outperform vote while only 40.59% of users gave Bausch + Lomb an outperform vote.
Bausch + Lomb currently has a consensus target price of $15.54, indicating a potential upside of 24.09%. Smith & Nephew has a consensus target price of $28.00, indicating a potential downside of 7.08%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Smith & Nephew.
In the previous week, Bausch + Lomb had 3 more articles in the media than Smith & Nephew. MarketBeat recorded 10 mentions for Bausch + Lomb and 7 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 0.48 beat Bausch + Lomb's score of 0.14 indicating that Smith & Nephew is being referred to more favorably in the news media.
Bausch + Lomb has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Smith & Nephew has a net margin of 0.00% compared to Bausch + Lomb's net margin of -6.62%. Bausch + Lomb's return on equity of 3.35% beat Smith & Nephew's return on equity.
Smith & Nephew has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.
Summary
Smith & Nephew beats Bausch + Lomb on 12 of the 18 factors compared between the two stocks.
Get Bausch + Lomb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch + Lomb Competitors List
Related Companies and Tools
This page (NYSE:BLCO) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy BLCO Stock Free BLCO Stock Alerts